Regencell Bioscience Holdings Limited balance sheet RGC
As of Jun 30, 2026, Regencell Bioscience Holdings Limited had total assets of $14.7 million and total liabilities of $1.4 million. Total assets were up 155.9% from a year earlier. Stockholders' equity was $13.3 million. It held $14.2 million in cash and investments against $295,811 of total debt, net cash of $13.9 million. The current ratio, current assets divided by current liabilities, was 10.77.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash |
14
+486.7%
|
2
-18.3%
|
3
+89.2%
|
2
-75.6%
|
6
+10700.7%
|
0
|
| Short-term investments |
—
|
2
-50.4%
|
5
-50.0%
|
10
+0.0%
|
10
|
—
|
| Cash and investments |
14
+486.7%
|
5
-38.5%
|
8
-31.2%
|
12
-29.6%
|
16
+27532.0%
|
0
|
| Total current assets |
14
+190.1%
|
5
-39.6%
|
8
-30.2%
|
12
-29.3%
|
16
+24499.6%
|
0
|
| Property and equipment, net |
0
-37.3%
|
0
+52.0%
|
0
-67.8%
|
0
-38.1%
|
1
+770.5%
|
0
|
| Total assets |
15
+155.9%
|
6
-31.8%
|
8
-33.1%
|
13
-30.0%
|
18
+5197.6%
|
0
|
| Liabilities and equity | ||||||
| Total current liabilities |
1
+99.0%
|
1
+242.8%
|
0
-68.1%
|
1
+5.0%
|
1
-86.7%
|
4
|
| Total liabilities |
1
+54.2%
|
1
+307.9%
|
0
-65.3%
|
1
-32.6%
|
1
-78.4%
|
4
|
| Stockholders' equity |
13
+174.7%
|
5
-40.9%
|
8
-31.7%
|
12
-29.5%
|
17
+526.9%
|
-4
|
| Debt | ||||||
| Lease liabilities |
0
-45.7%
|
1
+535.0%
|
0
-81.5%
|
0
-39.9%
|
1
|
—
|
| Total debt |
0
-45.7%
|
1
+535.0%
|
0
-81.5%
|
0
-39.9%
|
1
|
—
|
| Net cash |
14
+641.3%
|
4
-44.7%
|
8
-29.1%
|
11
-29.0%
|
16
|
—
|
| Ratios | ||||||
| Current ratio |
10.77x
|
7.39x
|
41.92x
|
19.15x
|
28.46x
|
0.02x
|
| Debt to equity |
0.02x
|
0.11x
|
0.01x
|
0.04x
|
0.05x
|
—
|
| Return on equity |
-87.66%
|
-73.75%
|
-52.34%
|
-48.80%
|
—
|
—
|
| Return on assets |
-79.45%
|
-62.27%
|
-50.98%
|
-46.52%
|
—
|
-395.95%
|
| Book value per share |
0.03
|
0.01
|
0.02
|
0.92
|
1.31
|
-0.40
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RGC (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- Hong Kong
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1829667
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.